OBJECTIVE： To analyze the clinical application of human serum albumin in China from 2001 to 2017 by using bibliometric method， so as to summarize the level of clinical rational use of human serum albumin in China， and provide evidence to regulate use of it. METHODS： Retrieved from CNKI， VIP， Wanfang database， related literatures about clinical rational use of human serum albumin in China were collected during Jan. 2001-Dec. 2017. Type， general information （publication time， publication area distribution， journal distribution） and specific content （co-word analysis， hospital level， department， indication， evaluation evidence and results， intervention measures） of included literatures were analyzed. The regularity was summarized to put forward the suggestions. RESULTS： All of 581 literatures were included， involving 98 valid literatures， among which there were 83 retrospective investigations and 15 intervention literatures. The number of literature was in increasing tendency after 2015， the most in 2016 （16 literatures）. The publications area were mainly concentrated in Jiangsu， Zhejiang， Beijing and Fujian. Totally 98 literatures were published by 50 kinds of journals. Top 3 journals in the list of publication number were China Pharmacy （7 literatures）， Chinese Journal of Pharmacoepidemiology （5 literatures） and Evaluation and Analysis of Drug-Use in Hospitals of China （5 literatures）. Results of co-word analysis included “human serum albumin” “clinical application” “rational drug use” “analysis” “investigation” “retrospective investigation” “clinical pharmacist” “evidence-based medicine” etc. The total number of cases was 68 197 cases. The albumin was mostly common used in third grade hospitals （73 hospitals）； top 4 departments were ICU， cardiothoracic surgery department， general surgery department， and digestive disease department. Among indication， hypoalbuminemia （17.2％） and nutritional support（13.7％） still took up a significant proportion， but 6.4％ belonged to no indication. In only 27.3％ literatures， compliance rate of indications in drug package inserts was higher than 50％， while the rate was only 8.9％ with the UHC guidelines. Among 15 intervention literatures， intervention methods included the participation of clinical pharmacists， establishment of evaluation system or model， formulation of management approval system， prescription review， etc. CONCLUSIONS： Clinical application of human albumin related research has increased year by year， and more and more attention has been paid to it. But the level of research is uneven in different regions. There is no uniform standard for the application of human serum albumin in China. To improve rational drug use level， develop national guidelines should be developed as soon as possible， intervenient measures should be adopted and strengthened so as to standardize rational use of human serum albuminand avoid waste of resources.